Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of oral vinorelbine with capecitabine and trastuzumab in HER2-positive metastatic breast cancer
2004-000748-26Phase 2Completed
- Sponsor
- Pierre Fabre Laboratories
- Start
- Oct 2004
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vinorelbine, capecitabine and trastuzumab in HER2-enriched breast cancer (HER2+), sponsored by Pierre Fabre Laboratories. Primary endpoint: Overall response rate. Started Oct 2004; status: completed.
02
Drugs
03
Conditions
HER2-enriched breast cancer (HER2+)
Beyond the preview
Go deeper on 2004-000748-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000748-26.